Antares Pharma (ATRS) Announces Earnings Results

Antares Pharma (NASDAQ:ATRS) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01, MarketWatch Earnings reports. Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. The company had revenue of $17.87 million during the quarter, compared to the consensus estimate of $15.13 million.

Shares of ATRS stock traded down $0.07 during trading hours on Wednesday, hitting $3.54. 1,389,427 shares of the company’s stock were exchanged, compared to its average volume of 1,265,544. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.33 and a quick ratio of 1.89. The company has a market cap of $547.88 million, a price-to-earnings ratio of -32.18 and a beta of 0.55. Antares Pharma has a fifty-two week low of $1.58 and a fifty-two week high of $3.93.

ATRS has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $4.50 target price on shares of Antares Pharma in a research note on Wednesday. BidaskClub downgraded Antares Pharma from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. ValuEngine downgraded Antares Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Finally, Jefferies Financial Group upped their target price on Antares Pharma to $8.00 and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $5.44.

In related news, Director Jacques Gonella sold 49,507 shares of the stock in a transaction on Monday, August 13th. The stock was sold at an average price of $3.09, for a total value of $152,976.63. Following the completion of the transaction, the director now directly owns 9,985,848 shares of the company’s stock, valued at approximately $30,856,270.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert F. Apple sold 43,000 shares of the stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $3.75, for a total value of $161,250.00. Following the completion of the transaction, the chief executive officer now directly owns 1,573,562 shares of the company’s stock, valued at $5,900,857.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 492,507 shares of company stock valued at $1,830,227. Corporate insiders own 12.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY raised its stake in Antares Pharma by 127.0% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $133,000 after purchasing an additional 28,875 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Antares Pharma by 533.6% in the 1st quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 377,824 shares during the last quarter. Perkins Capital Management Inc. raised its stake in Antares Pharma by 37.0% in the 3rd quarter. Perkins Capital Management Inc. now owns 435,000 shares of the specialty pharmaceutical company’s stock valued at $1,462,000 after purchasing an additional 117,500 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Antares Pharma by 4.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 744,188 shares of the specialty pharmaceutical company’s stock valued at $1,921,000 after purchasing an additional 32,626 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Antares Pharma by 27.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,135,517 shares of the specialty pharmaceutical company’s stock valued at $2,930,000 after purchasing an additional 245,032 shares during the last quarter. 38.62% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Antares Pharma (ATRS) Announces Earnings Results” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/11/07/antares-pharma-atrs-announces-earnings-results.html.

About Antares Pharma

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: Fundamental Analysis

Earnings History for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply